I see the Moles are back, hiya Moles! You thought I left? Never. Here's a refresher, for anyone new or who missed it the first time. Just throw these Buyout Moles on ignore, after you have a good chuckle at their naivete. Remember boys and girls.....
NEVER
A
BUYOUT

Quote:

---

NEVER a buyout. Anyone even entertaining numbers is either a mole or extremely shortsighted. Why? Dividends....

https://www.dividend.com/dividend-stocks/heal...ction=desc

Quote:

AMGN
Amgen
Price: $234.53
Dividend: $6.40
Yield: 2.66%

GILD
Gilead Sciences
Price: $76.19
Dividend: $2.7200
Yield: 3.57%

TECH
Techne Corp
Price: $260.00
Dividend: $1.2800
Yield: 0.49%




Imagine, if you will, Leronlimab being SOC for JUST HIV. Only HIV.
Number of patients x Doses x Frequency.

What does that put the share price at?

How long does it take for CYDY to have more cash than it knows what to do with, and they declare a dividend?

How much will the dividend be?

Imagine it's $1.25 a year. What is your cost basis / PPS on your entry? Divide $1.25 by that, that would be your annual yield on those shares.

Multiply it by the number of shares you have... would it be nice to get that, every year?

What if the dividend is higher than $1.25 a year? What if it's $2.50? $5?

Where else are you going to get a guaranteed annual yield like that?

Now factor in CV19, cancers, ARDS, "ohm's list":
https://investorshangout.com/post/view?id=5723002

Quote:


An incomplete list of potential treatments targets for leronlimab.

Alzheimer's
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Coeliac Disease
Chronic Fatigue Syndrome
COPD
COVID-19 (and other corona viruses)
Crohn's Disease
Colitis
Dermatomyositis
Diabetes (type 1)
Duchenne Muscular Dystrophy (possibly other muscular dystrophys also)
Emphysema
Fibromyalgia
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Hepatitis (autoimmune)
HIV
Idiopathic Pulmonary Fibrosis
Inflammatory Bowel Disease
Influenza (severe)
Lambert-Eaton Syndrome
Lupus
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Neurofibromatosis
Parkinson's Disease
Pemphigus
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sickle Cell Disease (anti-inflammatory effect)
Sjogren’s Syndrome
Stroke
Tuberculosis
Vasculitis

Read More: https://investorshangout.com/post/view?id=572...z6MsG2xwS7


Sure, there will be capital gains for every indication Leronlimab is effective for. Those will be insane... a safe, easy to administer (subcutaneous / "insulin shot like" , easy to store and transport treatment for a whole slew of immune diseases and disorders....

But those gains get lost when another company siphons up the drug: Leronlimab's profits will go to prop up other (probably less significant / successful) projects, massive bloated advertising budgets, an army of middlemen and overpaid officers. If you think issuing a few million shares is dilution, try getting absorbed into a $20+ billion company when you're under $2 Billion.

So are the dividends. Poof!

Now, if anyone can tell me what opportunity on this planet is going to be better in the next 5-10 years ... what is going to have capital gains like that and probably annual dividends like that, that you need a buyout to happen now so you can rush to make significantly better gains there..... if anyone can tell me what that opportunity is, I'll vote for a buyout at around a $100 billion valuation in the next two weeks.

If anyone can't... there's not a chance in h---.. NEVER a buyout.

Read More: https://investorshangout.com/post/view?id=581...z6Y1toeyWK

---